These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36788038)

  • 1. High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases.
    Zhang Y; Luo S; Gao Y; Tong W; Sun S
    Angiology; 2024 May; 75(5):441-453. PubMed ID: 36788038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?
    Razavi AC; Jain V; Grandhi GR; Patel P; Karagiannis A; Patel N; Dhindsa DS; Liu C; Desai SR; Almuwaqqat Z; Sun YV; Vaccarino V; Quyyumi AA; Sperling LS; Mehta A
    J Clin Endocrinol Metab; 2024 Jan; 109(2):321-332. PubMed ID: 37437107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ; Le Goff W; Guerin M; Kontush A
    Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
    Zhou R; Stouffer GA; Smith SC
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL and HDL subfractions, dysfunctional HDL: treatment options.
    Garcia-Rios A; Nikolic D; Perez-Martinez P; Lopez-Miranda J; Rizzo M; Hoogeveen RC
    Curr Pharm Des; 2014; 20(40):6249-55. PubMed ID: 24953394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
    Xue H; Zhang M; Liu J; Wang J; Ren G
    Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of HDL in atherosclerotic cardiovascular disease.
    Schoch L; Alcover S; Padró T; Ben-Aicha S; Mendieta G; Badimon L; Vilahur G
    Clin Investig Arterioscler; 2023; 35(6):297-314. PubMed ID: 37940388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
    Hersberger M; von Eckardstein A
    Handb Exp Pharmacol; 2005; (170):537-61. PubMed ID: 16596814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
    Kastelein JJP; Hsieh A; Dicklin MR; Ditmarsch M; Davidson MH
    Curr Atheroscler Rep; 2024 Feb; 26(2):35-44. PubMed ID: 38133847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of statins on high-density lipoproteins.
    Schaefer EJ; Asztalos BF
    Curr Atheroscler Rep; 2006 Jan; 8(1):41-9. PubMed ID: 16455013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.
    Linton MF; Yancey PG; Tao H; Davies SS
    Circ Res; 2023 May; 132(11):1521-1545. PubMed ID: 37228232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HDL - Quo vadis].
    von Eckardstein A; März W; Laufs U
    Dtsch Med Wochenschr; 2023 May; 148(10):627-635. PubMed ID: 37080216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.